- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
$4.75 million grant to fund stem-cell work
The Lincy Foundation has given the first installment of a 4-year, $4.75 million grant to the Oregon Retinal Degeneration Center at Oregon Health & Science (OHSU) Casey Eye Institute.
Portland, OR-The Lincy Foundation has given the first installment of a 4-year, $4.75 million grant to the Oregon Retinal Degeneration Center at Oregon Health & Science (OHSU) Casey Eye Institute.
The grant will be used to develop stem-cell therapies to treat retinal degeneration, in particular age-related macular degeneration.
The grant will allow OHSU to be one of the only institutes in the country to test stem-cell therapies to prevent blindness from degenerative eye diseases. The grant will fund research from the initial stages through animal model testing and on to a phase I clinical trial to test the safety of the therapies in humans.
The Beverly Hills, CA-based Lincy Foundation is the primary philanthropic vehicle of billionaire investor Kirk Kerkorian.
